aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-10-30 19:44Core Points - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage [3][5] - The company's stock price plummeted by 83.2%, from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [3][4] Summary by Sections Allegations - The complaint alleges that aTyr Pharma made overwhelmingly positive statements while concealing material adverse facts about Efzofitimod's efficacy [3] - The truth about the drug's performance was revealed on September 15, 2025, when the company announced that the EFZO-FIT study failed to meet its primary endpoint [3] Stock Performance - Following the announcement of the study results, aTyr's stock experienced a significant decline of 83.2% in just one day [3][4] Next Steps for Shareholders - Shareholders who purchased shares during the class period (January 16, 2025, to September 12, 2025) are encouraged to register for the class action by December 8, 2025 [4] - Registered shareholders will receive updates through a portfolio monitoring software [4] Law Firm Information - The Gross Law Firm is leading the class action and aims to protect investors' rights against deceit and fraud [5] - The firm emphasizes its commitment to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5]